PriceTargets.com logo

Inventiva - IVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.22
  • Forecasted Upside: 163.35%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 2 Strong Buy Ratings
$6.16 As of 01/30/2026 05:00 PM ET
▼ -0.16 (-2.53%)

This chart shows the closing price for IVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inventiva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVA

Analyst Price Target is $16.22
▲ +163.35% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is $16.22, with a high forecast of $26.00 and a low forecast of $10.00. The average price target represents a 163.35% upside from the last price of $6.16.

This chart shows the closing price for IVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Inventiva. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/28/2026HC WainwrightSet TargetBuy ➝ Buy$24.00
1/27/2026BarclaysInitiated CoverageOverweight$18.00
1/27/2026BarclaysInitiated CoverageOverweight$18.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/12/2026Leerink PartnersInitiated CoverageOutperform$12.00
1/12/2026Leerink PartnersUpgradeStrong-Buy
1/7/2026UBS GroupInitiated CoverageNeutral ➝ Buy$3.00 ➝ $12.00
1/7/2026UBS GroupReiterated RatingNeutral ➝ Buy$3.00 ➝ $12.00
11/18/2025GuggenheimLower TargetBuy ➝ Buy$13.00 ➝ $11.00
11/6/2025Wolfe ResearchUpgradeStrong-Buy
11/5/2025Wolfe ResearchInitiated CoverageOutperform$13.00
11/5/2025Wolfe ResearchInitiated CoverageOutperform$13.00
10/9/2025HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $24.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$20.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/3/2025HC WainwrightInitiated CoverageBuy$20.00
9/2/2025GuggenheimBoost TargetBuy ➝ Buy$9.00 ➝ $13.00
8/27/2025Piper SandlerInitiated CoverageOverweight$26.00
4/4/2025GuggenheimLower TargetBuy ➝ Buy$12.00 ➝ $9.00
3/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
2/21/2025TD CowenInitiated CoverageBuy$10.00
1/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
11/22/2024Stifel NicolausLower TargetBuy ➝ Buy$20.00 ➝ $17.00
11/12/2024UBS GroupInitiated CoverageNeutral$3.00
10/15/2024HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $13.00
9/26/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $14.00
9/26/2024Stifel NicolausLower TargetBuy ➝ Buy$25.00 ➝ $20.00
4/8/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$12.00 ➝ $20.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00
2/16/2024Stifel NicolausLower TargetBuy ➝ Buy$27.00 ➝ $25.00
1/5/2024Lifesci CapitalReiterated RatingOutperform
12/21/2023HC WainwrightLower TargetBuy ➝ Buy$36.00 ➝ $24.00
10/27/2023Canaccord Genuity GroupInitiated CoverageBuy$12.00
10/27/2023Canaccord Genuity GroupInitiated CoverageBuy$12.00
9/21/2023Roth MkmReiterated RatingBuy ➝ Buy$11.00
9/1/2023GuggenheimReiterated RatingBuy ➝ Buy$12.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
5/31/2023Roth MkmInitiated CoverageBuy$11.00
5/19/2023Societe GeneraleUpgradeSell ➝ Buy
3/31/2023HC WainwrightLower TargetBuy$36.00 ➝ $35.00
3/16/2023Stifel NicolausInitiated CoverageBuy
11/15/2022Societe GeneraleDowngradeBuy ➝ Sell
9/23/2022HC WainwrightLower TargetBuy$42.00 ➝ $36.00
11/22/2021HC WainwrightBoost TargetBuy$40.00 ➝ $42.00
9/22/2021HC WainwrightReiterated RatingBuy$38.00 ➝ $40.00
9/22/2021HC WainwrightBoost TargetBuy$38.00 ➝ $40.00
5/4/2021Roth MkmReiterated RatingBuy
3/15/2021Societe GeneraleReiterated RatingBuy ➝ Sell
3/8/2021Societe GeneraleDowngradeBuy ➝ Sell
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2025
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 6 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 5 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 4 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 8 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 8 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Inventiva logo
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Read More

Today's Range

Now: $6.16
Low: $5.90
High: $6.32

50 Day Range

MA: $5.05
Low: $4.04
High: $7.15

52 Week Range

Now: $6.16
Low: $2.23
High: $7.98

Volume

519,422 shs

Average Volume

630,488 shs

Market Capitalization

$899.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Inventiva?

The following equities research analysts have issued reports on Inventiva in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, Leerink Partners, Piper Sandler, TD Cowen, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for IVA.

What is the current price target for Inventiva?

0 Wall Street analysts have set twelve-month price targets for Inventiva in the last year. Their average twelve-month price target is $16.22, suggesting a possible upside of 163.3%. Piper Sandler has the highest price target set, predicting IVA will reach $26.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $10.00 for Inventiva in the next year.
View the latest price targets for IVA.

What is the current consensus analyst rating for Inventiva?

Inventiva currently has 1 sell rating, 7 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IVA will outperform the market and that investors should add to their positions of Inventiva.
View the latest ratings for IVA.

What other companies compete with Inventiva?

Other companies that are similar to Inventiva include ADMA Biologics, Arcellx, NewAmsterdam Pharma, Viking Therapeutics and Centessa Pharmaceuticals. Learn More about companies similar to Inventiva.

How do I contact Inventiva's investor relations team?

Inventiva's physical mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The company's listed phone number is 33-3-80-44-75-00 and its investor relations email address is [email protected]. The official website for Inventiva is www.inventivapharma.com. Learn More about contacing Inventiva investor relations.